• Conference Proceeding

Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States

Citation

Brogan, A., Talbird, S. E., Thompson, J. R., Kim, Y. A., Olson, J., Peterson, J., ... Pietrandoni, G. (2013). Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States. In [16], pp. A343–A344. .

Abstract